Signal Genetics™ is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
The MyPRS™ (Myeloma Prognostic Risk Signature™) test is a microarray-based gene expression profiling (GEP) assay used to assist the management of patients with multiple myeloma (MM) and related disorders.
Click the link above to open the Physician Web Portal and Genetic Test Results Analysis Tool in a new window. This portal will provide immediate, secure access to key information to improve cancer treatment decisions. Registration is required.